$DNLI
Denali Therapeutics Inc. Stock $dnli

$dnli Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000171489922000144 Filed on November 03, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$10.28M	$3.559M
YoY Change	-17.83%	-32.66%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$23.52M	$23.26M
YoY Change	8.07%	20.39%
% of Gross Profit
Research & Development	$92.11M	$87.79M
YoY Change	35.7%	22.68%
% of Gross Profit
Depreciation & Amortization	$4.091M	$2.141M
YoY Change	95.37%	-2.1%
% of Gross Profit
Operating Expenses	$115.6M	$111.0M
YoY Change	29.0%	22.19%
Operating Profit		-$107.5M
YoY Change		25.58%
Interest Expense	$6.660M	$4.187M
YoY Change	418.29%	316.62%
% of Operating Profit
Other Income/Expense, Net		$4.187M
YoY Change		316.62%
Pretax Income	-$98.68M	-$103.3M
YoY Change	30.13%	22.12%
Income Tax	-$6.000K	$0.00
% Of Pretax Income
Net Earnings	-$98.68M	-$103.3M
YoY Change	31.11%	22.12%
Net Earnings / Revenue	-959.62%	-2902.47%
Basic Earnings Per Share		-$0.84
Diluted Earnings Per Share	-$0.74	-$0.84
COMMON SHARES
Basic Shares Outstanding	135.8M shares	123.3M shares
Diluted Shares Outstanding		123.5M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.336B	$1.106B
YoY Change	54.4%	6.44%
Cash & Equivalents	$218.0M	$118.6M
Short-Term Investments	$1.118B	$987.4M
Other Short-Term Assets	$36.10M	$32.47M
YoY Change	17.98%	114.47%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.372B	$1.139B
YoY Change	52.95%	7.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$44.09M	$41.69M
YoY Change	13.44%	4.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Other Assets	$13.40M	$16.12M
YoY Change	12.87%	326.71%
Total Long-Term Assets	$87.92M	$89.08M
YoY Change	-82.66%	-77.42%
TOTAL ASSETS
Total Short-Term Assets	$1.372B	$1.139B
Total Long-Term Assets	$87.92M	$89.08M
Total Assets	$1.460B	$1.228B
YoY Change	3.99%	-15.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.790M	$7.539M
YoY Change	-41.62%	56.51%
Accrued Expenses	$66.69M	$61.15M
YoY Change	25.44%	36.88%
Deferred Revenue	$0.00	$23.00K
YoY Change	-100.0%	-98.26%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$363.9M	$360.7M
YoY Change	-3.79%	564.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$379.0K	$379.0K
YoY Change	0.0%	-45.93%
Total Long-Term Liabilities	$379.0K	$379.0K
YoY Change	0.0%	-45.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$363.9M	$360.7M
Total Long-Term Liabilities	$379.0K	$379.0K
Total Liabilities	$417.8M	$416.3M
YoY Change	-5.44%	-4.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$971.0M	-$872.3M
YoY Change	50.54%	53.11%
Common Stock	$1.686M	$1.564M
YoY Change	8.91%	1.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.042B	$811.3M
YoY Change
Total Liabilities & Shareholders Equity	$1.460B	$1.228B
YoY Change	3.99%	-15.34%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$98.68M	-$103.3M
YoY Change	31.11%	22.12%
Depreciation, Depletion And Amortization	$4.091M	$2.141M
YoY Change	95.37%	-2.1%
Cash From Operating Activities	-$72.66M	-$57.05M
YoY Change	10.95%	37.68%
INVESTING ACTIVITIES
Capital Expenditures	$4.849M	-$6.050M
YoY Change	-258.83%	222.67%
Acquisitions
YoY Change
Other Investing Activities	-$122.7M	$21.47M
YoY Change	225.52%	-141.99%
Cash From Investing Activities	-$127.6M	$15.42M
YoY Change	213.03%	-129.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	299.7M	5.154M
YoY Change	5698.2%	55.48%
NET CHANGE
Cash From Operating Activities	-72.66M	-57.05M
Cash From Investing Activities	-127.6M	15.42M
Cash From Financing Activities	299.7M	5.154M
Net Change In Cash	99.43M	-36.47M
YoY Change	-198.37%	-59.98%
FREE CASH FLOW
Cash From Operating Activities	-$72.66M	-$57.05M
Capital Expenditures	$4.849M	-$6.050M
Free Cash Flow	-$77.51M	-$51.00M
YoY Change	24.14%	28.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001714899
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38311
	dei	Entity Registrant Name EntityRegistrantName	Denali Therapeutics Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3872213
	dei	Entity Address Address Line1 EntityAddressAddressLine1	161 Oyster Point Blvd
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	866-8548
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	DNLI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	135813668	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	118615000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	293477000	usd
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	987440000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	571930000	usd
CY2022Q3	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	0	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1226000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	32471000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	30601000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	1138526000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	897234000	usd
CY2022Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0	usd
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	425449000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41692000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38865000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	31271000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30743000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16117000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11871000	usd
CY2022Q3	us-gaap	Assets Assets	1227606000	usd
CY2021Q4	us-gaap	Assets Assets	1404162000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	7539000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4779000	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1443000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13253000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19013000	usd
CY2022Q3	dnli	Accrued Clinical And Other Research And Development Costs Current AccruedClinicalAndOtherResearchAndDevelopmentCostsCurrent	21701000	usd
CY2021Q4	dnli	Accrued Clinical And Other Research And Development Costs Current AccruedClinicalAndOtherResearchAndDevelopmentCostsCurrent	15887000	usd
CY2022Q3	dnli	Other Accrued Manufacturing Costs Current OtherAccruedManufacturingCostsCurrent	16732000	usd
CY2021Q4	dnli	Other Accrued Manufacturing Costs Current OtherAccruedManufacturingCostsCurrent	9955000	usd
CY2022Q3	dnli	Other Accrued Costs And Other Liabilities Current OtherAccruedCostsAndOtherLiabilitiesCurrent	2395000	usd
CY2021Q4	dnli	Other Accrued Costs And Other Liabilities Current OtherAccruedCostsAndOtherLiabilitiesCurrent	2857000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7068000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5453000	usd
CY2022Q3	dnli	Contract With Customer Liability From Related Parties Current ContractWithCustomerLiabilityFromRelatedPartiesCurrent	290516000	usd
CY2021Q4	dnli	Contract With Customer Liability From Related Parties Current ContractWithCustomerLiabilityFromRelatedPartiesCurrent	292386000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	23000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	27915000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	360670000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	378245000	usd
CY2022Q3	dnli	Contract With Customer Liability From Related Parties Noncurrent ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent	276000	usd
CY2021Q4	dnli	Contract With Customer Liability From Related Parties Noncurrent ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent	1295000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3398000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	54978000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	58554000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	379000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	379000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	416303000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	441871000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	123796438	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	123796438	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	122283305	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	122283305	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	1564000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1548000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1693901000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1608238000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-11853000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2499000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-872309000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-644996000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	811303000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	962291000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1227606000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1404162000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	184000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5285000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	94805000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36143000	usd
CY2022Q3	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	3375000	usd
CY2021Q3	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	usd
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	3375000	usd
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	4000	usd
CY2022Q3	us-gaap	Revenues Revenues	3559000	usd
CY2021Q3	us-gaap	Revenues Revenues	5285000	usd
	us-gaap	Revenues Revenues	98180000	usd
	us-gaap	Revenues Revenues	36147000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	87786000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	71559000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	266621000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	197477000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23259000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19319000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	66959000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57300000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	111045000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	90878000	usd
	us-gaap	Operating Expenses OperatingExpenses	333580000	usd
	us-gaap	Operating Expenses OperatingExpenses	254777000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-107486000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-85593000	usd
	dnli	Research And Development Expense Offset From Related Party Cost Reimbursement ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement	5300000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-235400000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-218630000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4187000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1005000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8114000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3310000	usd
CY2022Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-103299000	usd
CY2021Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-84588000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-227286000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-215320000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	27000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-103299000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-84588000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-227313000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-215320000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	421000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-153000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-9354000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-276000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-102878000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-84741000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-236667000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-215596000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.84
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.85
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.85
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.77
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.77
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	123473390	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123473390	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	121742067	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121742067	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	123054889	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123054889	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	121309197	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121309197	shares
CY2022Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	200000	usd
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	2900000	usd
CY2021Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	900000	usd
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	2500000	usd
CY2022Q3	dnli	Due To Related Parties Expense Current DueToRelatedPartiesExpenseCurrent	1400000	usd
	dnli	Due To Related Parties Expense Current DueToRelatedPartiesExpenseCurrent	3800000	usd
CY2021Q3	dnli	Research And Development Expense Offset From Related Party Cost Reimbursement ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement	1200000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	962291000	usd
	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	11019000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	74660000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-227313000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9354000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	811303000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	884448000	usd
CY2022Q3	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	5154000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24579000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-103299000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	421000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	811303000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1150531000	usd
	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	14180000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	63162000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-215320000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-276000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1012277000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	1072705000	usd
CY2021Q3	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	3315000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20998000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-84588000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-153000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1012277000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-227313000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-215320000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6292000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6499000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	74660000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	63162000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-1430000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-6316000	usd
	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	2488000	usd
	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	2201000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-51000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1386000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8049000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3989000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3783000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6891000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3036000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-31290000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10601000	usd
	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	-2889000	usd
	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	-2546000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-172053000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-145895000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	628330000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1191491000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12984000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5447000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	627486000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1216062000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13828000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19124000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	11019000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	14180000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11019000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14180000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-174862000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-112591000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	294977000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	508644000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120115000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	396053000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	284000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	29000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the Condensed Consolidated Balance Sheets and Statements of Operations and Comprehensive Loss.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. Substantially all of the Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government and its agencies, as well as institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Condensed Consolidated Balance Sheets. As of September 30, 2022 and December 31, 2021, the Company had no off-balance sheet concentrations of credit risk. </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other clinical-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. Further, the company is also subject to broad market risks and uncertainties resulting from recent events, such as the COVID-19 pandemic, the Russian invasion of Ukraine, inflation, rising interest rates, and recession risks as well as supply chain and labor shortages.</span></div>
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	999527000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	usd
CY2022Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1094668000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1262673000	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	111000	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	111000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	998942000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11502000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	987440000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2149000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	997379000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P1Y
CY2022Q3	us-gaap	Revenues Revenues	3559000	usd
CY2021Q3	us-gaap	Revenues Revenues	5285000	usd
	us-gaap	Revenues Revenues	98180000	usd
	us-gaap	Revenues Revenues	36147000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	610816	shares
CY2022Q3	us-gaap	Lease Cost LeaseCost	3306000	usd
CY2021Q3	us-gaap	Lease Cost LeaseCost	2863000	usd
	us-gaap	Lease Cost LeaseCost	8857000	usd
	us-gaap	Lease Cost LeaseCost	8429000	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	2899000	usd
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	2618000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	8193000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	7717000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y7M6D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2996000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12238000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.02
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	12122000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11793000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	12182000	usd
CY2022Q3	dnli	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	29966000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	81297000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	19251000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	62046000	usd
CY2022Q3	us-gaap	Sublease Income SubleaseIncome	1000000.0	usd
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	1000000.0	usd
	us-gaap	Sublease Income SubleaseIncome	2900000	usd
	us-gaap	Sublease Income SubleaseIncome	2900000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	758000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	3096000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	876000	usd
CY2022Q3	dnli	Lessor Operating Lease Payment To Be Received After Year Two LessorOperatingLeasePaymentToBeReceivedAfterYearTwo	0	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	4730000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13686386	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	24.33
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2168090	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	43.54
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	14.23
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	495030	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	40.64
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14748630	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13137935	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	30.25
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9553685	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	21.08
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24579000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20998000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	74660000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	63162000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18400000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16500000	shares

Files In Submission

Name	View Source	Status
0001714899-22-000144-index-headers.html	Edgar Link	pending
0001714899-22-000144-index.html	Edgar Link	pending
0001714899-22-000144.txt	Edgar Link	pending
0001714899-22-000144-xbrl.zip	Edgar Link	pending
dnli-20220930.htm	Edgar Link	pending
dnli-20220930.xsd	Edgar Link	pending
exhibit311q32022.htm	Edgar Link	pending
exhibit312q32022.htm	Edgar Link	pending
exhibit321q32022.htm	Edgar Link	pending
exhibit322q32022.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
dnli-20220930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dnli-20220930_lab.xml	Edgar Link	unprocessable
dnli-20220930_pre.xml	Edgar Link	unprocessable
dnli-20220930_htm.xml	Edgar Link	completed
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
dnli-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DNLI
Denali Therapeutics Inc. Stock $dnli

2022 Q4 Form 10-Q Financial Statement

#000171489922000144 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNLI Denali Therapeutics Inc. Stock $dnli

2022 Q4 Form 10-Q Financial Statement

#000171489922000144 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNLI
Denali Therapeutics Inc. Stock $dnli